A New Alternative for Cancer-associated Venous Thromboembolism?

Synopsis: Low–molecular-weight heparin has been the drug of choice for cancer-associated venous thromboembolism, but oral Xa inhibitors may be equally effective. Source: Raskob G, Verhamme P, Carrier M, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2017.
Source: Clinical Pulmonary Medicine - Category: Respiratory Medicine Tags: Pulomonary Trends Source Type: research